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Synergistic anti-Campylobacter
jejuni activity of fluoroquinolone and
macrolide antibiotics with phenolic
compounds
Euna Oh and Byeonghwa Jeon*
School of Public Health, University of Alberta, Edmonton, AB, Canada
The increasing resistance of Campylobacter to clinically important antibiotics, such as
fluoroquinolones and macrolides, is a serious public health problem. The objective of this
study is to investigate synergistic anti-Campylobacter jejuni activity of fluoroquinolones
and macrolides in combination with phenolic compounds. Synergistic antimicrobial
activity was measured by performing a checkerboard assay with ciprofloxacin and
erythromycin in the presence of 21 phenolic compounds. Membrane permeability
changes in C. jejuni by phenolic compounds were determined by measuring the level of
intracellular uptake of 1-N-phenylnaphthylamine (NPN). Antibiotic accumulation assays
were performed to evaluate the level of ciprofloxacin accumulation in C. jejuni. Six
phenolic compounds, including p-coumaric acid, sinapic acid, caffeic acid, vanillic acid,
gallic acid, and taxifolin, significantly increased the susceptibility to ciprofloxacin and
erythromycin in several human and poultry isolates. The synergistic antimicrobial effect
was also observed in ciprofloxacin- and erythromycin-resistant C. jejuni strains. The
phenolic compounds also substantially increased membrane permeability and antibiotic
accumulation in C. jejuni. Interestingly, some phenolic compounds, such as gallic acid
and taxifolin, significantly reduced the expression of the CmeABC multidrug efflux
pump. Phenolic compounds increased the NPN accumulation in the cmeB mutant,
indicating phenolic compounds may affect the membrane permeability. In this study,
we successfully demonstrated that combinational treatment of C. jejuni with antibiotics
and phenolic compounds synergistically inhibits C. jejuni by impacting both antimicrobial
influx and efflux.
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INTRODUCTION
Campylobacter jejuni is one of the leading bacterial causes of human gastroenteritis worldwide
(Butzler, 2004). It is estimated that Campylobacter accounts for approximately 400–500 million
infection cases worldwide per year (Ruiz-Palacios, 2007). C. jejuni inhabits the gastrointestinal
tracts of poultry as a commensal microorganism; thus, the consumption of undercooked poultry is
the most frequent cause of human infections with C. jejuni (Ruiz-Palacios, 2007). C. jejuni can
also spread by cross-contamination and during inadequate storage (Cogan et al., 1999; Luber
et al., 2006). Particularly, the dissemination of foodborne pathogens via hands and food-contact
surfaces of food processing equipment has been well documented by a number of researchers
(Kusumaningrum et al., 2003; Van Asselt et al., 2008).
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For the clinical treatment of serious campylobacteriosis,
ﬂuoroquinolones and macrolides are drugs of choice
(Luangtongkum et al., 2009). However, the increasing resistance
to the clinically important antibiotics in C. jejuni is widespread
worldwide and signiﬁcantly compromised the eﬀectiveness
of current antibiotic chemotherapy, frequently leading to
severe patient outcomes, such as prolonged hospitalization,
high mortality, and treatment failure (Helms et al., 2005).
For example, ciproﬂoxacin resistance is approximately 92%
in C. jejuni isolates from raw chicken in South Korea (Han
et al., 2007) and even 100% in clinical isolates from children in
Thailand (Serichantalergs et al., 2007). Among the antibiotic
resistance determinants in C. jejuni, the multidrug eﬄux
pump CmeABC is most well-characterized (Lin et al., 2002;
Martinez and Lin, 2006). CmeABC is a resistance-nodulation-
cell division (RND) type of multidrug eﬄux pump and consists
of three protein components, including periplasmic fusion
protein (i.e., CmeA), an inner membrane drug transporter (i.e.,
CmeB), and outer membrane protein (i.e., CmeC) (Lin et al.,
2002).
Phenolic compounds are a group of secondary metabolites
present in a wide range of plants. The beneﬁcial health
eﬀects of dietary supplementation of phenolic compounds have
been reported in a signiﬁcant number of studies, regarding
their anti-oxidation, anti-cancer, anti-diabetic, and anti-aging
activities (Pandey and Rizvi, 2009). Additionally, some phenolic
compounds possess antimicrobial activities against various
pathogenic bacteria (Daglia, 2012), including C. jejuni (Klancnik
et al., 2012). The CmeABC eﬄux pump plays an important
role in C. jejuni resistance to phenolic compounds (Klancnik
et al., 2012). Recently, we also demonstrated that some
phenolic compounds exhibit anti-C. jejuni activity (Oh and Jeon,
2015). In this study, we investigated the anti-Campylobacter
activity of combinational treatment of phenolic compounds with
antibiotics of clinical importance for the treatment of human
campylobacteriosis.
MATERIALS AND METHODS
Bacterial Strains and Culture Conditions
Campylobacter jejuni NCTC 11168 is the wild-type strain
(Parkhill et al., 2000), and C. jejuni CR64 and ER641 are NCTC
11168 derivatives resistant to ciproﬂoxacin and erythromycin,
respectively. Brieﬂy, C. jejuni CR64 and ER641 were generated
by increasing the antibiotic concentrations in culture media from
0.1 μg ml−1 to 64 μg ml−1. We chose resistant C. jejuni strains
by growing on MH agar plates supplemented with 64 μg ml−1
of ciproﬂoxacin and erythromycin, and mutations in gyrA and
23S rRNA, respectively, were observed by sequencing (data not
shown). C. jejuni P1 and P2 were isolated from retail poultry
meats. C. jejuni HCJ4132 and HCJ2316 are human isolates, a
kind gift fromDr.Monika Keelan (University of Alberta). A cmeB
mutant of C. jejuni NCTC 11168 was reported previously (Akiba
et al., 2006). C. jejuni strains were routinely grown on Mueller–
Hinton (MH) medium at 42◦C under microaerobic conditions
(5% O2, 10% CO2, and 85% N2).
Checkerboard Titration Assay
The MICs of ciproﬂoxacin and erythromycin were measured
in the presence of phenolic compounds, including 13 phenolic
acids (p-coumaric acid, caﬀeic acid, sinapic acid, ferulic
acid, cinnamic acid, vanillic acid, salicylic acid, gallic acid,
benzoic acid, p-hydroxybenzoic acid, tannic acid, protocatechuic
acid, and syringic acid) and eight ﬂavonoids [epigallocatechin
gallate, (-)-epicatechin, morin, quercetin, chrysin, naringenin,
hesperidin, and taxifolin] with C. jejuni NCTC 11168. For
C. jejuni P1, P2, HCJ4132, HCJ2316, CR64, and ER641
strains, the MICs of ciproﬂoxacin and erythromycin were
measured in combination with p-coumaric acid, sinapic acid,
caﬀeic acid, vanillic acid, gallic acid, and taxifolin. All these
phenolic compounds were purchased from Sigma–Aldrich
(St. Louis, MO, USA). The checkerboard titration assay was
performed as described previously (Hsieh et al., 1993). Brieﬂy,
antibiotics were twofold serially diluted on each column, and
phenolic compounds were twofold diluted on each row. The
concentrations of phenolic compounds and antibiotics started
from their MICs. C. jejuni suspension (ca., 105 CFU per well)
was added, and the plate was incubated at 42◦C for 18 h under
microaerobic conditions.
Membrane Permeability Test
Membrane permeability assay was performed as described
elsewhere (Helander and Mattila-Sandholm, 2000). Brieﬂy,
overnight cultures of C. jejuni strains were diluted in MH broth
to an OD600 of 0.07. The C. jejuni suspensions in MH broth
were grown at various concentrations of phenolic compounds,
including 1–128 μg ml−1 of p-coumaric acid, 0.5–64 μg ml−1
of gallic acid, or 0.25–32 μg ml−1 of taxifolin, at 42◦C for
18 h under microaerobic conditions. The bacterial cells were
harvested by centrifugation and washed twice with PBS (pH
7.4) and resuspended with 100 μl PBS containing 10 μM 1-
N-phenylnaphthylamine (NPN) for 5 min. EDTA was used as
a positive control for permeability (Hancock and Wong, 1984).
Fluorescence was measured at 335/405 nm (excitation/emission)
with FLUOstar Omega (BMG Labtech, Germany).
Ciprofloxacin Accumulation Assay
A ciproﬂoxacin accumulation assay was performed according
to a method described previously (Jeon et al., 2011). Brieﬂy,
C. jejuni NCTC 11168 was grown overnight to around the late
log phase in MH broth with 1–128 μg ml−1 of p-coumaric acid,
gallic acid, and taxifolin. The bacterial cells were harvested and
washed once with PBS (pH 7.4), and then resuspended in PBS.
The phenolic compounds did not aﬀect the growth of C. jejuni
since the MICs of p-coumaric acid, gallic acid, and taxifolin are
1024 μg ml−1, 512 μg ml−1, and 256 μg ml−1, respectively
(Oh and Jeon, 2015). These samples were incubated at 37◦C for
10 min, and ciproﬂoxacin was added to a ﬁnal concentration
of 10 μg ml−1. After incubation at room temperature for
20 min, the bacterial suspension (0.5 ml) was diluted with
2.5 ml of ice-cold PBS and centrifuged at 6000 × g, 4◦C for
10 min. After washing twice with ice-cold PBS, the harvested
cells were resuspended in 0.2 ml of 0.1 M glycine hydrochloride
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(pH 3.0) and incubated at room temperature with shaking
for 16 h. The supernatant was obtained by centrifugation at
15000 × g for 10 min, and ﬂuorescence was measured at
279/447 nm (excitation/emission) with FLUOstar Omega (BMG
Labtech).
PcmeABC::lacZ Promoter Fusion Assay
C. jejuni NCTC 11168 including PcmeABC ::lacZ was constructed
previously (Hwang et al., 2012). C. jejuni was grown
overnight on MH agar including kanamycin (50 μg ml−1)
at 42◦C under microaerobic conditions. C. jejuni was
harvested and diluted in MH broth to an OD600 of 0.07.
C. jejuni was grown at 42◦C for 5 h under microaerobic
conditions and then was exposed to 1 μg ml−1of each
phenolic compound for 2 h. β-galactosidase assays were
carried out as described in a previous study (Kim et al.,
2015).
Western Blot Analysis
Campylobacter jejuni NCTC 11168 was grown on MH agar
plates and harvested in fresh MH broth as described above.
Broth culture of C. jejuni were grown at 42◦C for 7 h under
microaerobic conditions with shaking (200 rpm) in present
of 1 μg ml−1 of phenolic compounds, including p-coumaric
acid, sinapic acid, caﬀeic acid, vanillic acid, gallic acid, and
taxifolin. Western blot analysis was performed as described
previously (Lin et al., 2002) with a 10% polyacrylamide gel
in Tris-Tricine buﬀer. The polyclonal antibody against CmeA
is a kind gift from Dr. Qijing Zhang (Iowa State University,
USA).
RESULTS
Synergistic Antimicrobial Effect of
Phenolics with Antibiotics
Twenty one phenolic compounds, including 13 phenolic acids
and eight ﬂavonoids, were screened to examine synergistic
antimicrobial activity with ciproﬂoxacin and erythromycin. The
MICs of the phenolic compounds were already determined in
our previous study and are mostly greater than 256 μg ml−1
(Oh and Jeon, 2015). Synergistic antimicrobial activity was
observed in six phenolic compounds, including ﬁve phenolic
acids (p-coumaric acid, sinapic acid, caﬀeic acid, vanillic
acid, gallic acid) and one ﬂavonoid (taxifolin; Table 1 and
Supplementary Tables S1–S7). For example, 8 μg ml−1 of the
six phenolic compounds resulted in approximately 4–32-fold
reduction in the MICs of ciproﬂoxacin and erythromycin
in ﬁve diﬀerent C. jejuni strains, including three human
isolates (NCTC 11168, HCJ 4132, and HCJ 2316) and two
poultry isolates (P1 and P2; Table 1 and Supplementary
Tables S3–S7). A further MIC reduction was observed at
increased concentrations of phenolic compounds; the MIC
of ciproﬂoxacin was reduced by 64-fold in combination
with 128 μg ml−1 p-coumaric acid, vanillic acid, taxifolin,
and 256 μg ml−1 sinapic acid, vanillic acid, and gallic acid
in C. jejuni NCTC11168 (Supplementary Table S3). The
fractional inhibitory concentration (FIC) index is frequently
used to evaluate if the reaction is synergistic or not; the
FIC values of 0.5 or less indicate synergy (Rand et al.,
1993). The FIC values also conﬁrmed that the increased
antimicrobial activity is synergistic in C. jejuni NCTC
TABLE 1 | Synergistic antimicrobial activity of phenolic compounds with ciprofloxacin and erythromycin in various Campylobacter jejuni strains.
Ciprofloxacin MIC (µg ml−1) in the presence of phenolic compounds
C. jejuni
11168
C. jejuni
CR64
C. jejuni
P1
C. jejuni
P2
C. jejuni
HCJ4132
C. jejuni
HCJ2316
p-Coumaric acid 0.063 (8) 8 (8) 0.004 (32) 0.125 (8) 0.016 (16) 0.016 (16)
Sinapic acid 0.063 (8) 8 (8) 0.016 (8) 0.063 (16) 0.031 (8) 0.031 (8)
Caffeic acid 0.125 (4) 16 (4) 0.031 (4) 0.125 (8) 0.031 (8) 0.031 (8)
Vanillic acid 0.063 (8) 8 (8) 0.008 (16) 0.25 (4) 0.031 (8) 0.031 (8)
Gallic acid 0.063 (8) 8 (8) 0.008 (16) 0.125 (8) 0.016 (16) 0.031 (8)
Taxifolin 0.063 (8) 2 (32) 0.008 (16) 0.063 (16) 0.031 (8) 0.031 (8)
Ciprofloxacin without phenolic compounds 0.5 (1) 64 (1) 0.125 (1) 1 (1) 0.25 (1) 0.25 (1)
Erythromycin MIC (µg ml−1) in the presence of phenolic compounds
C. jejuni
11168
C. jejuni
ER641
C. jejuni
P1
C. jejuni
P2
C. jejuni
HCJ4132
C. jejuni
HCJ2316
p-Coumaric acid 0.125 (4) 16 (4) 0.063 (8) 0.125 (8) 0.25 (1) 0.063 (4)
Sinapic acid 0.063 (8) 16 (4) 0.063 (8) 0.125 (8) 0.125 (2) 0.063 (4)
Caffeic acid 0.125 (4) 16 (4) 0.063 (8) 0.25 (4) 0.125 (2) 0.125 (2)
Vanillic acid 0.125 (4) 16 (4) 0.125 (4) 0.25 (4) 0.125 (2) 0.125 (2)
Gallic acid 0.063 (8) 16 (4) 0.125 (4) 0.125 (8) 0.063 (4) 0.063 (4)
Taxifolin 0.031 (16) 4 (16) 0.031 (16) 0.063 (16) 0.063 (4) 0.031 (8)
Erythromycin without phenolic compounds 0.5 (1) 64 (1) 0.5 (1) 1 (1) 0.25 (1) 0.25 (1)
The results are representative of three independent experiments. The table indicates the levels of MIC and fold changes in parenthesis. The concentration of phenolic
compounds is 8 μg ml−1. Synergistic effects in a wide range of phenolic concentrations are listed in Supplementary Tables S3–S8.
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11168 (Supplementary Table S9). These results clearly show
that some phenolic compounds synergistically enhance the
antimicrobial activity of ciproﬂoxacin and erythromycin against
C. jejuni.
Synergistic Antimicrobial Activity of
Phenolic Compounds against
Antibiotic-Resistant C. jejuni
To further investigate the synergistic antimicrobial activity of
phenolic compounds against antibiotic-resistant C. jejuni, we
performed a checkerboard assay with C. jejuni CR64 and
ER641 strains; C. jejuni CR64 is ﬂuoroquinolone-resistant
due to a C257T mutation in gyrA, and C. jejuni ER641 is
resistant to erythromycin because of an A2074C mutation in
23S rRNA. Interestingly, a substantial synergistic antimicrobial
eﬀect was also observed in the resistant strains (Supplementary
Table S8). Particularly, 8 μg ml−1 taxifolin reduced the
MICs of ciproﬂoxacin and erythromycin by 32- and 16-
fold, respectively (Table 1). The synergistic antimicrobial
activity was dependent on the concentration of phenolic
compounds (Supplementary Table S8). These ﬁndings exhibit
that phenolic compounds sensitizes resistant C. jejuni strains to
antibiotics.
Increased Membrane Permeability by
Phenolic Compounds
Since some phenolic compounds have been reported to
aﬀect membrane permeability in other Gram-negative bacteria
(Nohynek et al., 2006; Borges et al., 2013), we investigated if
phenolic compounds would change membrane permeability in
C. jejuni NCTC 11168. Two phenolic acids (i.e., p-coumaric
acid and gallic acid) and one ﬂavonoid (i.e., taxifolin),
which consistently exhibited synergistic anti-Campylobacter
activity with ciproﬂoxacin and erythromycin (Table 1 and
Supplementary Table S3), were chosen for the permeability
assay with NPN. The NPN uptake rates were increased
in a manner dependent on the concentration of phenolic
compounds (Figure 1). Membrane permeability was signiﬁcantly
increased at concentrations as low as 0.5 μg ml−1 gallic
acid, 1 μg ml−1 taxifolin and 16 μg ml−1 p-coumaric
acid (Figure 1). A few other phenolic compounds, such as
caﬀeic acid, vanillic acid, and sinapic acid, also increased
the membrane permeability in C. jejuni. However, other
phenolic compounds did not show changes in membrane
permeability in C. jejuni (Supplementary Figure S1). EDTA,
a permeability enhancement agent, was used as a positive
control; a high concentration (0.5 mM) of EDTA increased
membrane permeability. The six phenolic compounds (i.e.,
p-coumaric acid, gallic acid, taxifolin, caﬀeic acid, vanillic acid,
and sinapic acid) enhanced the membrane permeability at an
EDTA concentration (0.02 mM) that did not aﬀect membrane
permeability (Supplementary Figure S2). This conﬁrmed the
eﬀect of phenolic compounds on the alteration of membrane
permeability. These ﬁndings indicated that some phenolic
compounds may signiﬁcantly aﬀect membrane permeability in
C. jejuni.
FIGURE 1 | Changes in the membrane permeability of Campylobacter
jejuni by p-coumaric acid (A), gallic acid (B), and taxifolin (C). The assay
was carried out with 10 μM 1-N-phenylnaphthylamine (NPN). Fluorescence
from samples with NPN treatment reflects permeability increase, and RFU
from samples without NPN shows the background fluorescence level. The
results show the means and standard deviations of triplicate samples in a
single experiment. The experiment was repeated three times, and all the
experiments produced similar results. Statistical significance was determined
with two-way ANOVA using GraphPad Prism 6 (GraphPad Software Inc.,
USA). ns: P > 0.5, ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001.
Increased Antibiotic Accumulation by
Phenolic Compounds
Since we observed that phenolic compounds increased
membrane permeability in C. jejuni NCTC 11168 (Figure 1), we
determined if phenolic compounds may also increase antibiotic
accumulation in C. jejuni. An antibiotic accumulation assay was
performed with ciproﬂoxacin in the presence of p-coumaric
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acid, gallic acid, and taxifolin. Interestingly, ciproﬂoxacin
accumulation in C. jejuni was substantially enhanced by the
phenolic compounds. For example, 8 μg ml−1 p-coumaric acid,
FIGURE 2 | Increased accumulation of ciprofloxacin in C. jejuni by
p-coumaric acid (A), gallic acid (B), and taxifolin (C). The results show
the means and standard deviations of triplicate samples in a single
experiment. Similar results were obtained in three independent experiments.
Statistical analysis was carried out with the Student’s t-test using GraphPad
Prism 6 (GraphPad Software Inc.). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001,
∗∗∗∗P < 0.0001.
and 2 μg ml−1 gallic acid and taxifolin increased the level of
ciproﬂoxacin accumulation approximately by twofold, compared
to a non-treated control (Figure 2). The results show that
phenolic compound treatment enhances antibiotic accumulation
in C. jejuni.
Changes in CmeABC Expression by
Phenolic Compounds
Since CmeABC is a key resistance determinant in C. jejuni, we
examined if the phenolic compounds would aﬀect the expression
of CmeABC in C. jejuni. First, we determined the level of
cmeABC transcription in the presence of phenolic compounds
by using a PcmeABC ::lacZ fusion. Interestingly, the phenolic
compounds overall reduced cmeABC transcription. Particularly,
gallic acid and taxifolin resulted in most signiﬁcant reduction
in the level of cmeABC transcription (Figure 3A). Western
blotting results also showed that phenolic compounds, especially
gallic acid and taxifolin, decreased the translational levels of
CmeA (Figure 3B). As to the other phenolic compounds, the
translational levels were not consistent with the transcriptional
FIGURE 3 | Changes in the expression levels of CmeABC by phenolic
compounds. (A) Transcriptional levels of cmeABC determined by a
PcmeABC::lacZ promoter fusion system with 1 μg ml−1 phenolic compounds.
The results exhibit the means and standard deviations of triplicate samples in
a single experiment. The experiment was repeated three times. Statistical
analysis was performed with Student’s t-test using GraphPad Prims 6
(GraphPad Software Inc.). ns: P > 0.5, ∗P < 0.05, ∗∗P < 0.01. (B) The level of
CmeA protein was demonstrated by western blotting with phenolic
compounds. The CmeABC efflux pump was differentially expressed by
phenolic compounds. Phenolic compounds (1 μg ml−1) were treated on each
sample.
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levels. For example, vanillic acid, caﬀeic acid, and p-coumaric
reduced the level of cmeABC transcription; however, the
reduction was not observed at the translational level in our
repeated experiments. These results suggest some phenolic
compounds, such as gallic acid and taxifolin, aﬀect CmeABC
expression.
Combinational Effects of Phenolic
Compounds on CmeABC and Membrane
Permeability
Some phenolic compounds signiﬁcantly increased the membrane
permeability (Figure 1) and reduced CmeABC expression
(Figure 3). However, it was not clear how phenolic compounds
aﬀect membrane permeability interactively via CmeABC and
the membrane integrity in C. jejuni. To elucidate this, we
performed a membrane permeability assay with a cmeB
mutant in the presence of phenolic compounds and/or
EDTA. Taxifolin and p-coumaric acid made the cmeB mutant
accumulate more NPN than WT (i.e., C. jejuni NCTC 11168;
Figure 4). The NPN accumulation was increased in the cmeB
mutant by EDTA and further by combination of EDTA with
phenolic compounds (Figure 4). Although phenolic compounds
diﬀerentially aﬀected the NPN accumulation between WT and
the cmeB mutant, phenolic compounds commonly increased
the NPN accumulation in both WT and the cmeB mutant.
These results suggest that the increased NPN accumulation
by phenolic compounds would be associated with both the
CmeABC drug eﬄux pump and the alteration in membrane
permeability.
DISCUSSION
By screening 21 phenolic compounds, in this study, we
identiﬁed six phenolic compounds that substantially increased
the antimicrobial activity of ciproﬂoxacin and erythromycin
against several C. jejuni strains from humans and poultry
(Table 1 and Supplementary Tables S1–S7), including strains
with antibiotic resistance (Table 1 and Supplementary Table
S8). Although the level of MIC reduction slightly varied
depending on the strain, the phenolic compounds signiﬁcantly
sensitized C. jejuni to antibiotics. The synergism has been
reported in some other bacteria. Green tea extracts containing
polyphenols signiﬁcantly decreased the MIC of oxacillin in
Staphylococcus aureus (Cho et al., 2008). Gallic acid increases
the antimicrobial eﬃcacy of amikacin, norﬂoxacin, gentamicin,
and sulfamethoxazole in Escherichia coli (Neyestani et al.,
2007). The synergistic antimicrobial activity of phenolics has
been demonstrated even in an animal model. Treatment of
chronic bacterial prostatitis with ciproﬂoxacin in combination
with catechin, a ﬂavonoid, signiﬁcantly decreases the growth
of E. coli even in animal experiments using rats (Lee et al.,
2005). To the best of our knowledge, this is the ﬁrst report
about synergistic antimicrobial activity between antibiotics and
phenolic compounds in C. jejuni.
The synergistic antimicrobial activity of phenolic compounds
is associated with the alteration in membrane permeability
FIGURE 4 | Membrane permeability changes in C. jejuni NCTC 11168
(WT) and its isogenic cmeB mutant by p-coumaric acid (A), gallic acid
(B), and taxifolin (C). The NPN permeabilization assay was performed with
10 μM NPN. In the assay, 1 μg ml−1 phenolic compounds and 0.05 mM
EDTA were used. Similar results were produced in three independent
experiments. Statistical analysis was carried out with Student’s t-test using
GraphPad Prism 6 (GraphPad Software INC.). ns: P > 0.5, ∗P < 0.05,
∗∗P < 0.01, ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001.
and antibiotic accumulation in C. jejuni (Figures 1 and 2).
Borges et al. (2013) reported that gallic acid relatively at high
concentrations (i.e., >100 μg ml−1) increases membrane
permeability in Gram-negatives and -positives, such as E. coli,
Pseudomonas aeruginosa, and Listeria monocytogenes. Compared
to these pathogens, however, gallic acid eﬀectively reduced
permeability in C. jejuni at signiﬁcantly low concentrations.
For example, 2 μg ml−1 gallic acid resulted in twofold
increases in permeability (Figure 1B) and antibiotic
accumulation (Figure 2B), and an eightfold reduction in
the MIC of ciproﬂoxacin (Table 1), suggesting that C. jejuni
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is more likely to be permeabilized by phenolics than these
pathogenic bacteria. Although its molecular mechanism
remains unknown, presumably, it could be because C. jejuni
possesses lipooligosaccharide (LOS), not lipopolysaccharide
(LPS). Surface polysaccharides, particularly LPS, constitute
a critical permeability barrier to the entry of hydrophobic
compounds into the cell (Vaara, 1992); in our previous
study, we also demonstrated LOS is a permeability barrier
to phenolic compounds in C. jejuni (Oh and Jeon, 2015).
It would be likely that short LOS may easily expose the
outer membrane of C. jejuni to hydrophobic phenolic
compounds compared to long LPS structures. Taxifolin is
an antioxidant that scavenges free radicals (Anthony and
Saleh, 2013). Although the membrane permeabilizing eﬀect
of taxifolin has not been reported in bacteria, in this study,
we also demonstrated that taxifolin signiﬁcantly aﬀects
membrane permeability (Figure 1C), antibiotic accumulation
(Figure 2C), and susceptibility in C. jejuni (Table 1 and
Supplementary Tables S1–S8). p-Coumaric acid is known
as an antioxidant that decreases the peroxidation of low-
density lipoprotein (LDL; Zang et al., 2000). Garrait et al.
(2006) suggested that p-coumaric acid is a less metabolized
phenolic antioxidant in rat model that may have greater health
beneﬁts. p-Coumaric acid possesses antimicrobial activities
against Gram-positives and -negatives, and aﬀects the membrane
integrity in Shigella dysenteriae (Lou et al., 2012). In addition,
p-coumaric acid binding to DNA to inhibit cellular functions
that may cause cell death in S. dysenteriae (Lou et al.,
2012). p-Coumaric acid signiﬁcantly enhanced membrane
permeability and drug accumulation in C. jejuni (Figures 2A
and 3A).
In some other bacteria, phenolic compounds may aﬀect
the expression of drug eﬄux pumps. Biochanin A, a
phenolic compound from plants, exhibits an eﬄux pump
inhibition activity in Mycobacterium smegmatis (Lechner
et al., 2008). In contrast, exposure to a combination of
phenolic compounds activates the expression of the acrA
and emrA drug eﬄux pump genes in Erwinia chrysanthemi,
a Gram-negative plant pathogen (Ravirala et al., 2007). In
this study, some phenolic compounds reduced the expression
level of CmeABC (Figure 3), an RND-type multidrug eﬄux
pump that plays a key role in antimicrobial resistance in
C. jejuni (Lin et al., 2002). Based on the ﬁndings in this
study and reports from others, phenolic compounds may
have diﬀerential, either negative or positive, eﬀects on the
expression of drug eﬄux pumps. Even though the reduced
expression of CmeABC by phenolic compounds may result
in the increased accumulation of ciproﬂoxacin (Figures 2
and 3), it cannot completely explain the synergistic eﬀect of
phenolic compounds. For example, p-coumaric acid signiﬁcantly
increased ciproﬂoxacin accumulation (Figure 2A) and exhibited
substantial synergistic anti-C. jejuni activity with ciproﬂoxacin
and erythromycin (Table 1) without aﬀecting the protein
level of CmeA (Figure 3B). Therefore, the increase in
permeability and ciproﬂoxacin accumulation by p-coumaric
acid might be related to the changes in membrane permeability
and antibiotic inﬂux. Taken together, the synergistic eﬀects
of phenolic compounds may involve at least two possible
mechanisms: (1) phenolic compounds increase inﬂux of
antibiotics by permeabilizing the bacterial membrane, and (2)
they inhibit the activity of the major eﬄux pump CmeABC.
This hypothesis is supported by our ﬁndings that phenolic
compounds increased the NPN accumulation even in the
cmeB mutant where the function of CmeABC is inactivated
(Figure 4).
The development of antimicrobial adjuvants that inhibit
the function of resistance determinants is considered as a
novel approach to curb antibiotic resistance (Wright, 2000),
because this alternative strategy may re-sensitize pathogens
to antibiotics and enhance the utility of existing antibiotics
(Wright, 2000; Pages and Amaral, 2009). The ﬁndings in
this study suggest that phenolic compounds could be used
as a dietary adjuvant for antibiotic treatment of human
infections with Campylobacter. Phenolic compounds are rich
in foods of plant origin. For instance, one gram chestnut
contains about 24.9 mg of gallic acid (Bennett et al.,
2009) and one gram chokeberry has 1.4 mg of caﬀeic acid
(Zheng and Wang, 2003). Since the site of Campylobacter
infection is the gastrointestinal tracts, and antibiotics are
generally administered orally for the treatment of foodborne
infection with Campylobacter, possibly, the consumption of
diets containing high levels of phenolic compounds may
synergistically inhibit Campylobacter in the intestines. To prove
this hypothesis, however, further experiments are required
to examine the synergistic anti-Campylobacter eﬀect in vivo,
although the lack of suitable infection models for Campylobacter
may be an issue for this. Nevertheless, our ﬁndings in
this study successfully suggest the possibility that phenolic
compounds may potentially be used for dietary therapy to
treat human infections with Campylobacter with antibiotic
resistance.
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